On 15-17 September an exhibition within the framework of the VII
All-Russia Forum “Health of the Nation is the Basis of Russia’s
Prosperity” took place. “National Biotechnology”, a Russian producer of
human recombinant full cycle insulin, presented a project of a new
manufacturing complex for the production of drugs, the construction of
the complex being underway.
The All-Russia Forum “Health of the Nation is the Basis of Russia’s
Prosperity” is an annual event of the National Health League and the
Ministry of Public Health and Social Development of the Russian
Federation. The Forum is the most extensive federal platform for the
demonstration of the state and corporate programs, projects, services
and goods for healthy lifestyle.
The exhibition stand of “National Biotechnology”, being a part of the
Moscow Region projects’ exposition, was visited by Leo Bokeriya, the
president of the all-Russian public organization of the National Health
League, and by Vladimir Semenov, the Minister of Health of the Moscow
Region, who emphasized the relevance of the implemented project for the
Russian pharmaceutical branch and the country in general.
The high tech automated manufacturing complex of “National
Biotechnology” OAO is being built in the town of Obolensk in Serpukhov
District of the Moscow Region. New production capacities allow the
company to scale up the existing production of human recombinant insulin
(Rinsulin R and Rinsulin NPH), launch an industrial line of insulin
cartridges and insulin analogs production. Moreover, the new factory
will produce original state-of-the-art drugs for the treatment and
prevention of diabetes and other socially significant diseases.
The factory’s production capacities account for 20 million vials and 5
million cartridges per year. Investments in the first construction
stage exceed 400 million rubles. The end of construction and the
production site commissioning are planned for the second quarter of
2012. The layout of production premises, equipment placement and fitting
will be carried out with regard to the current versions of the RF
effective norms and standards, including the EU Guidelines on Good
Manufacturing Practice for Medical Products of the European Commission
Today “National Biotechnology” OAO is the only Russian enterprise
producing human recombinant insulin using a full-cycle principle: from
substance synthesis to finished medical products. The substance quality
provided by “National Biotechnology” OAO was highly estimated by three
certified independent laboratories in Germany - Proteome Factory AG,
Protylic GmbH, Labor L + S AG, which confirmed compliance with the
European and American pharmacopeias.
The company produces a standard sample of human recombinant insulin,
which is used as a State Standard Reference Sample by the national
supervision bodies for testing drugs produced in Russia and imported
from other countries.
Since 2001, “Geropharm” has been a strategic partner of “National
Biotechnology” OAO and an exclusive distributor of its medical products.
“Building a new manufacturing complex was required in view of the company plans for capacity expansion as well as manufacturing of innovative products that are currently being developed,” said Peter Rodionov, the company CEO. “On a national scale high-quality domestic human recombinant full cycle insulin production and the building of a new industrial complex is a further step on the way to the import substitution program and the country’s medicinal security.”